Close
RNS Number : 1854P
ValiRx PLC
08 June 2020
 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

Directorate Change and Extension of Reporting deadline for publication of audited accounts for

year to 31 December 2019

 

London, UK, 8 June 2020: ValiRx (AIM:VAL) is pleased to announce that, further to the announcement of 1 May 2020, Dr Suzanne Dilly has been appointed as a director of the Company with immediate effect with the title Chief Executive Officer.

 

Following her appointment, the board comprises:-



Dr Suzanne Dilly

Chief Executive Officer

Mr Gerry Desler

Chief Financial Officer

Mr Kevin Alexander

Non-executive Director

Mr Martin Lampshire

Non-executive Director

 

As announced on 27 May 2020 Dr Kevin Cox will be appointed as Non-executive Chairman, following completion of normal regulatory due diligence, which is expected to be completed in the coming weeks.

 

The Company does not intend to make any further changes to the board in 2020.

 

Extension of deadline for publication of audited accounts to year to 31 December 2019

 

Due to the current COVID-19 outbreak, the Company will be unable to post its annual audited accounts to shareholders for the year to 31 December 2019 by the 30 June 2020 deadline pursuant to AIM Rule 19.

 

Further to the guidance provided by AIM Regulation in "Inside AIM" on 26 March 2020, the Company requested an additional period of up to three months to publish its annual audited accounts for the year ended 31 December 2019.

 

AIM Regulation has granted the extension, and therefore the Company will publish its annual audited accounts to 31 December 2019 by 30 September 2020.  The Company has also applied for and been granted an extension to delay the filing of its audited annual accounts by Companies House until 30 September 2020.

 

 

The following information is disclosed in respect of Dr Suzanne Dilly (age 42) pursuant to Schedule 2(g) of the AIM Rules for Companies:

 

Current directorships

Directorships and partnerships held in the past five years

ValiSeek Limited

Points North Consultancy Limited

Tangent Reprofiling Limited


 

Dr Suzanne Dilly holds 1,666,668 shares in the Company representing 0.46 per cent. of the Company's issued share capital.

 

There is no further information which is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Dr Suzanne Dilly.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Suzanne Dilly

Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

Tel: +44 (0) 20 7469 0930

 

 

Notes for Editors

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer. 

 

The Company's business model focuses on identifying and in-licensing early stage projects, adding value through scientific development and then out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the Company reduces risk while increasing the potential for realising value.

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAKZGGVLNLGGZM